Nebenwirkungen · Ultomiris
Ultomiris 300 mg/3 mL concentrate for solution for infusion Ultomiris 1 100 mg/11 mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-143201 · Präparat HOS-098946
Infusion-related reactions In clinical trials, infusion-related reactions were common (≥1%). These events, which were mild to moderate in severity and transient, included back pain, abdominal pain, muscle spasms, drop in blood pressure, elevation in blood pressure, rigors, limb discomfort, hypersensitivity (allergic reaction), dysgeusia (bad taste), and drowsiness. These reactions did not require discontinuation of ravulizumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:20:00Z · SHA-256 00e9c1aae169c90c13d7ad320dfbb3ab349e9f383abaa4a7cf15c55859699eb6 · Passage e4c50d6fd0a63fa9426da03b9cbc38e10ac37cd018ecf2c624c9ead8ba51f723 · Zeichen 4659–5090 im Abschnitt